amyloid
format
associ
multipl
amyloidosi
diseas
human
calcitonin
hct
typic
amyloidogen
peptid
aggreg
associ
medullari
carcinoma
thyroid
mtc
also
limit
clinic
applic
magnolia
officinali
tradit
chines
herbal
medicin
two
major
polyphenol
compon
magnolol
mag
honokiol
hon
display
multipl
function
polyphenol
like
flavonoid
deriv
extens
studi
amyloid
inhibitor
howev
antiamyloidogen
properti
biphenyl
backbon
contain
polyphenol
mag
hon
report
studi
two
compound
test
effect
hct
aggreg
found
mag
hon
inhibit
amyloid
format
hct
wherea
mag
show
stronger
inhibitori
effect
moreov
dosedepend
disassembl
preform
hct
aggreg
immunodot
blot
dynam
light
scatter
studi
suggest
mag
hon
suppress
aggreg
hct
oligomer
fibril
stage
mttbase
dyeleakag
assay
demonstr
mag
hon
effect
reduc
cytotox
caus
hct
aggreg
furthermor
isotherm
titrat
calorimetri
indic
mag
hon
interact
hct
togeth
studi
suggest
potenti
antiamyloidogen
properti
two
compound
structur
relat
deriv
amyloidogen
protein
capabl
misfold
assembl
amyloid
deposit
consid
import
caus
factor
amyloid
diseas
alzheim
diseas
parkinson
diseas
type
diabet
mellitu
patholog
situat
amyloidogen
protein
aggreg
oligom
follow
form
extens
linear
fibril
accompani
structur
transit
sheetrich
structur
studi
shown
oligomer
intermedi
toxic
speci
amyloid
aggreg
induc
cell
apoptosi
mostli
penetr
lipid
bilay
cell
membran
prevent
amyloid
protein
aggreg
toxic
conform
thu
becom
strategi
prevent
treat
amyloid
diseas
human
calcitonin
hct
blood
calcium
bone
resorpt
regul
peptid
secret
c
cell
thyroid
fig
origin
hct
use
treat
osteoporosi
paget
diseas
howev
due
high
intrins
tendenc
aggreg
low
bioactiv
result
aggreg
clinic
applic
hct
discontinu
fda
moreov
amyloid
deposit
hct
discov
patient
medullari
carcinoma
thyroid
mtc
indic
associ
mtc
hct
aggreg
therefor
salmon
calcitonin
sct
much
lower
aggreg
propens
share
homolog
hct
clinic
use
instead
howev
hct
much
higher
potenc
sct
sct
administr
caus
side
effect
like
anorexia
vomit
inhibit
hct
aggreg
thu
great
import
pharmaceut
prepar
hct
vitro
treatment
mtc
great
effort
made
identifi
inhibitor
suppress
aggreg
amyloidogen
protein
among
compound
deriv
herbal
medicin
extens
report
magnolia
officinali
tradit
chines
herbal
medicin
multipl
pharmaceut
activ
includ
elimin
damp
phlegm
reliev
distens
potenti
antitumor
properti
two
polyphenol
deriv
magnolia
officinali
magnolol
mag
honokiol
hon
major
effect
ingredi
known
antioxid
antitumor
antiinflammatori
neuroprotect
properti
recent
studi
also
suggest
mag
hon
exhibit
benefici
effect
induc
cytotox
hand
polyphenol
multipl
aromat
phenol
ring
regard
class
potenti
amyloid
inhibitor
flavonoid
along
deriv
studi
polyphenol
exampl
epigallocatechin
egcg
deriv
flavanon
extens
studi
antiamyloidogen
activ
synuclein
sevi
islet
amyloid
polypeptid
amyloid
current
undergo
phase
iiiii
clinic
studi
treat
alzheim
diseas
polyphenol
curcumin
caffeic
acid
also
report
howev
antiamyloidogen
properti
polyphenol
biphenyl
backbon
mag
hon
fig
determin
hct
use
model
test
antiamyloid
aggreg
properti
magnolol
honokiol
inhibit
amyloid
format
human
calcitonin
thioflavint
tht
fluoresc
base
assay
use
monitor
amyloid
format
hct
hct
gave
strong
tht
emiss
reach
plateau
stage
h
incub
lag
time
h
fig
b
control
addit
equimolar
amount
egcg
significantli
inhibit
aggreg
hct
fig
b
agre
previou
report
mag
hon
inhibit
hct
aggreg
dosedepend
manner
addit
equimolar
amount
mag
extend
lag
time
h
p
without
significantli
reduc
maximum
tht
fluoresc
intens
fig
howev
presenc
molar
excess
mag
maximum
tht
fluoresc
intens
substanti
decreas
control
accompani
prolong
lag
time
h
p
molar
ratio
increas
aggreg
hct
significantli
inhibit
lag
time
h
p
compar
mag
hon
less
potent
inhibit
hct
aggreg
presenc
equimolar
amount
hon
slightli
decreas
maximum
tht
fluoresc
intens
control
without
prolong
lag
time
fig
addit
amount
hon
show
stronger
inhibitori
effect
decreas
maximum
tht
fluoresc
intens
lag
time
prolong
h
p
h
p
respect
transmiss
electron
microscopi
tem
use
observ
morpholog
hct
aggreg
corrobor
tht
fluoresc
assay
result
h
incub
hct
form
extens
linear
fibril
fig
addit
equimolar
amount
egcg
significantli
inhibit
fibril
format
hct
fig
consist
previou
report
presenc
mag
hon
hct
show
obviou
fibril
h
incub
fig
amorph
aggreg
observ
hct
sampl
coincub
mag
hon
molar
ratio
fig
f
h
wherea
fewer
aggreg
observ
presenc
molar
amount
mag
hon
fig
j
mag
hon
hct
oligomer
fibril
determin
immunodot
blot
oc
antibodi
appli
detect
format
oligom
fibril
respect
hct
oligom
observ
h
incub
ocposit
fibril
emerg
h
incub
fig
presenc
equimolar
amount
egcg
neither
oligom
ocposit
fibril
observ
h
incub
agre
tem
result
fig
mag
hon
significantli
suppress
fibril
hct
presenc
two
compound
ocposit
fibril
observ
incub
except
presenc
equimolar
amount
mag
small
amount
fibril
detect
h
fig
mag
hon
also
inhibit
oligomer
hct
dosedepend
presenc
equimolar
amount
mag
hon
oligom
detect
h
incub
fig
molar
ratio
two
compound
increas
essenti
oligom
detect
antibodi
h
fig
particl
size
distribut
amyloid
aggreg
determin
dynam
light
scatter
dl
hct
observ
averag
diamet
aggreg
nm
h
incub
increas
nm
h
fig
addit
equimolar
amount
egcg
decreas
averag
diamet
nm
h
fig
presenc
equimolar
amount
mag
hon
show
signific
effect
size
hct
aggreg
display
averag
diamet
nm
nm
h
respect
fig
howev
molar
excess
mag
hon
ad
averag
diamet
hct
aggreg
significantli
decreas
nm
h
respect
fig
magnolol
honokiol
reduc
hct
aggreg
result
cytotox
membran
disrupt
effect
compound
hct
aggreg
induc
cytotox
studi
cell
mtt
assay
presenc
hct
h
reduc
cell
viabil
untreat
cell
fig
addit
equimolar
amount
egcg
significantli
increas
cell
viabil
p
presenc
mag
hon
reduc
cytotox
differ
extent
fig
addit
equimolar
amount
mag
increas
cell
viabil
p
molar
ratio
mag
increas
cell
viabil
increas
respect
p
contrast
presenc
equimolar
amount
hon
less
effect
mag
reduc
cytotox
cell
viabil
p
higher
concentr
hon
increas
cell
viabil
respect
p
sinc
three
compound
display
prolifer
effect
cell
fig
determin
whether
compound
also
reduc
cytotox
inhibit
aggreg
appli
fluoresc
dye
leakag
assay
determin
effect
mag
hon
membran
disrupt
caus
hct
model
membran
system
addit
hct
result
membran
disrupt
compar
vesicl
treat
triton
set
p
fig
addit
equimolar
amount
egcg
significantli
decreas
dye
leakag
p
presenc
mag
hon
dosedepend
protect
membran
equimolar
amount
two
compound
slightli
attenu
membran
penetr
respect
p
fig
higher
concentr
compound
almost
complet
abolish
membran
disrupt
p
fig
magnolol
honokiol
disaggreg
preform
hct
aggreg
efficaci
mag
hon
disaggreg
preform
hct
aggreg
determin
tht
fluoresc
assay
hct
preincub
h
form
aggreg
differ
amount
compound
ad
ad
equimolar
amount
mag
hon
show
obviou
disaggreg
effect
presenc
amount
either
compound
prevent
aggreg
hct
fig
b
molar
ratio
mag
hon
increas
hct
aggreg
disassembl
tht
fluoresc
intens
remark
reduc
untreat
control
h
incub
respect
fig
morpholog
hct
aggreg
disaggreg
observ
tem
addit
mag
hon
disaggreg
preform
hct
fibril
small
amorph
aggreg
fig
f
agre
tht
fluoresc
assay
result
quantit
solubl
hct
concentr
supernat
disaggreg
use
bicinchonin
acid
bca
assay
h
preincub
concentr
solubl
hct
supernat
lower
g
ml
fig
wherea
equimolar
amount
egcg
increas
hct
concentr
ca
gml
p
fig
equimolar
amount
mag
hon
show
obviou
disaggreg
effect
wherea
higher
concentr
significantli
increas
concentr
solubl
hct
supernat
gml
observ
h
incub
two
compound
fig
magnolol
honokiol
directli
bound
hct
determin
intermolecular
interact
hct
compound
isotherm
titrat
calorimetri
itc
use
measur
bind
affin
mag
hon
hct
describ
found
mag
bound
hct
k
b
h
calmol
calmoldeg
respect
figur
hon
bound
hct
k
b
h
calmol
calmoldeg
respect
figur
itc
measur
also
indic
mag
bound
hct
stoichiometri
hon
interact
hct
stoichiometri
toxic
aggreg
amyloidogen
protein
toxic
conform
caus
diseas
also
limit
clinic
applic
mani
proteinbas
drug
number
compound
thu
screen
design
amyloid
inhibitor
among
polyphenol
extens
report
mag
hon
two
biphenyl
backbon
contain
polyphenol
compound
found
effect
inhibit
aggreg
hct
mag
hon
directli
bound
hct
figur
dosedepend
suppress
hct
aggreg
fig
could
disassembl
preform
hct
aggreg
fig
oligomer
intermedi
form
aggreg
consid
toxic
conform
therefor
number
inhibitor
design
disrupt
oligomer
step
studi
mag
hon
found
effect
inhibit
oligomer
fibril
hct
fig
presenc
mag
hon
prolong
aggreg
lag
time
hct
impli
may
affect
aggreg
initi
oligomer
stage
fig
b
immunodot
blot
dl
assay
demonstr
compound
inhibit
format
hct
oligom
fibril
fig
reduc
membran
disrupt
cytotox
induc
hct
oligom
fibril
fig
gener
acknowledg
protein
aggreg
mostli
aromat
hydrophob
interact
aromat
interact
also
play
import
role
fibril
format
human
calcitonin
disrupt
interact
may
thu
suppress
amyloid
aggreg
nmr
investig
demonstr
egcg
bound
hct
intermolecular
stack
therefor
inhibit
aggreg
hct
use
itc
assay
found
mag
hon
bound
hct
consid
polyphenol
structur
two
molecul
fig
specul
mag
hon
may
also
bind
hct
aromat
interact
suppress
amyloid
format
hct
compar
hon
mag
display
similar
inhibitori
effect
low
equimolar
concentr
stronger
inhibitori
effect
high
concentr
itc
result
also
indic
mag
bound
hct
higher
bind
constant
compar
hon
figur
may
due
slight
structur
differ
two
compound
two
adjac
hydroxyl
mag
like
form
intramolecular
hydrogen
bond
caus
smaller
angl
two
benzen
ring
compar
hon
bind
hct
molecul
larger
angl
two
benzen
ring
may
produc
greater
steric
hindranc
may
explain
rel
lower
potenc
hon
compar
mag
inhibit
hct
aggreg
also
note
mag
hon
may
inhibit
hct
aggreg
differ
mechan
tht
fluoresc
assay
suggest
mag
increas
lag
time
inhibit
aggreg
oligomer
stage
wherea
hon
show
littl
effect
increas
lag
time
although
decreas
fibril
elong
rate
fig
b
itc
assay
also
suggest
mag
hon
bound
hct
stoichiometri
respect
figur
possibl
indic
differ
bind
site
hct
two
compound
notabl
dot
blot
assay
honokiol
show
stronger
inhibitori
effect
compar
magnolol
especi
equimolar
ratio
may
also
due
differ
interact
two
compound
lead
differ
conform
form
aggreg
interfer
dot
blot
result
howev
molecular
mechan
inhibitori
effect
mag
hon
hct
amyloid
format
remain
clarifi
great
interest
detect
monom
polym
form
aggreg
specif
monoclon
antibodi
use
western
blot
approach
tufail
et
al
describ
also
use
probe
exact
membran
protect
mechan
hon
mag
use
biophys
techniqu
particularli
use
highresolut
solidsst
nmr
approach
summari
studi
indic
mag
hon
inhibit
oligomer
fibril
hct
disassembl
hct
aggreg
higher
molar
ratio
importantli
reduc
membran
disrupt
cytotox
induc
hct
aggreg
result
suggest
potenti
antiamyloidogen
properti
mag
hon
polyphenol
biphenyl
backbon
may
explor
design
effect
antiamyloidosi
compound
human
calcitonin
obtain
gl
chemic
ltd
shanghai
china
mag
hon
egcg
aladdinreag
shanghai
china
antioligom
antibodi
oc
antifibril
antibodi
antirabbit
igg
obtain
merck
millipor
billerica
usa
thioflavint
tht
sodium
salt
popg
carboxyfluorescein
sigmaaldrich
st
loui
usa
cell
obtain
china
center
type
cultur
collect
cctcc
chemic
reagent
highest
grade
avail
sampl
prepar
hct
aggreg
conduct
protein
misfold
cyclic
amplif
pmca
approach
previous
describ
excit
emiss
wavelength
set
nm
nm
respect
curv
fit
previous
describ
experi
repeat
least
three
time
dot
blot
assay
dot
blot
assay
perform
previous
describ
briefli
sampl
spot
nitrocellulos
membran
biorad
hercul
usa
dri
min
blot
block
nonfat
milk
tbst
min
room
temperatur
incub
oc
antibodi
h
follow
coincub
secondari
antirabbit
igg
antibodi
h
room
temperatur
blot
incub
ecl
reagent
millipor
billerica
usa
min
develop
transmiss
electron
microscopi
tem
assay
tem
assay
perform
previous
describ
l
sampl
drop
onto
formvarcarbonco
copper
grid
air
dri
sampl
stain
uranyl
format
imag
observ
fei
tecnai
utwin
transmiss
electron
microscop
hillsboro
usa
dynam
light
scatter
dl
analysi
dynam
light
scatter
perform
zeta
pal
potenti
analyz
brookhaven
instrument
usa
describ
briefli
sampl
measur
scatter
angl
sampl
scan
three
time
minscan
data
analyz
multimod
size
distribut
msd
dye
leakag
assay
dye
leakag
assay
perform
previous
describ
popg
dissolv
chloroform
solvent
evapor
form
lipid
film
carboxyfluorescein
dissolv
mm
pb
final
concentr
mm
ad
lipid
film
scientif
report
doi
form
vesicl
vesicl
contain
carboxyfluorescein
purifi
column
sangon
biotech
shanghai
china
sampl
preincub
h
ad
popg
vesicl
final
peptid
concentr
fluoresc
intens
measur
mix
excit
emiss
wavelength
set
nm
respect
vesicl
treat
triton
complet
disrupt
vesicl
experi
repeat
least
three
time
mtt
cell
toxic
assay
mttbase
cell
toxic
assay
perform
previous
describ
cell
cultur
dmem
high
glucos
medium
contain
fb
penicillinstreptomycin
solut
sodium
pyruv
cell
plate
plate
densiti
cellswel
cultur
h
addit
fresh
medium
contain
hct
sampl
preincub
h
without
compound
cell
incub
anoth
h
l
mtt
mgml
ad
well
follow
addit
formazan
buffer
absorb
measur
nm
bicinchonin
acid
bca
assay
l
disaggreg
sampl
centrifug
rpm
min
l
supernat
withdrawn
ad
plate
l
bca
reagent
b
beyotim
china
mixtur
ad
sampl
incub
min
absorb
measur
nm
concentr
hct
calcul
refer
standard
curv
experi
repeat
least
time
itc
measur
itc
measur
perform
microc
vpitc
titrat
calorimet
ge
healthcar
usa
hct
compound
dissolv
mm
pb
ph
contain
mm
nacl
solut
degass
min
use
thermovac
ge
healthcar
usa
hct
use
titrant
sampl
cell
concentr
mag
mm
hon
mm
load
syring
compound
inject
hct
solut
consecut
inject
stir
rpm
first
inject
volum
l
durat
rest
inject
volum
l
inject
durat
control
experi
carri
inject
compound
pb
result
analyz
microc
origin
softwar
curv
fit
one
set
site
model
experi
repeat
three
time
data
express
mean
sd
kruskalw
test
mannwhitney
test
use
evalu
statist
signific
differ
consid
statist
signific
p
